1. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting E2A; 1994.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guidline.pdf
. Accessed 17 Nov 2016.
2. Camus P. Drug induced infiltrative lung diseases. In: Schwartz MI, King Jr TE, editors. Interstitial lung disease. 4th ed. Hamilton: BC Decker Inc; 2003. p. 485–534.
3. Kubo K, Nukiwa T, Hashimoto S, Fukuda Y, Tatsumi K, The Japanese Respiratory Society Committee for Formulation of Guideline Statement for the Diagnosis and Treatment of Drug Induced Lung Injuries, et al. The guideline statement for the diagnosis and treatment of drug induced lung injuries (Japanese). Tokyo: Medical Review Co.; 2006.
4. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, The Japanese Respiratory Society Committee for formulation of Consensus Statement for the Diagnosis and Treatment of Drug Induced Lung Injuries, et al. The guideline statement for the diagnosis and treatment of drug induced lung injuries (Japanese). Tokyo: Medical Review Co.; 2012.
5. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, The Japanese Respiratory Society Committee for Formulation of Consensus Statement for the Diagnosis and Treatment of Drug Induced Lung Injuries, et al. The Guideline statement for the diagnosis and treatment of drug induced lung injuries. Respir Investig. 2013;51:360–77.